TY - JOUR T1 - Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01778-2017 SP - 1701778 AU - Scott K. Heysell AU - Shahriar Ahmed AU - Md. Toufiq Rahman AU - Md. Wahiduzzaman Akhanda AU - A. Tucker Gleason AU - Andrew Ebers AU - Eric R. Houpt AU - Sayera Banu Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/01/05/13993003.01778-2017.abstract N2 - World Health Organization (WHO) recommendations for multidrug-resistant tuberculosis (MDR-TB) include 8+ months of an aminoglycoside such as kanamycin or amikacin or capreomycin, or a shorter course of 4+ months depending on the susceptibility of the patient's Mycobacterium tuberculosis isolate to other drugs in the regimen [1]. Aminoglycosides can produce significant side effects including irreversible ototoxicity, estimated to occur in 25–60% of patients treated for MDR-TB, depending on methods of measurement [2–5]. Even if surviving to cure, MDR-TB treatment itself is impoverishing [6] while ototoxicity further limits a patient's ability to regain employment and may compound social isolation.High frequency hearing loss from Kanamycin in MDR TB treatment: not if, but when?FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. ER -